ライフサイエンスコーパス: oxycodone

1 otent opioids (90.2% received hydrocodone or oxycodone).

2 ed 1,070 patients (288 buprenorphine and 782 oxycodone).

3 ged from 6.4 muM for dextrorphan to 2 mM for oxycodone).

4 ted pain plus a prescription for morphine or oxycodone.

5 ant during specific time periods, especially oxycodone.

6 commonly prescribed opioids were codeine and oxycodone.

7 oid-treated patients received codeine and/or oxycodone.

8 without affecting non-fentanyl opioids like oxycodone.

9 e brain hypoxia induced by moderate doses of oxycodone.

10 f patients who received buprenorphine versus oxycodone.

11 Rs after chronic treatment with morphine and oxycodone.

12 are prenatally exposed to opioids, including oxycodone.

13 prescription rates were for hydrocodone and oxycodone.

14 gastrointestinal effects in comparison with oxycodone.

15 in transcriptional regulation in response to oxycodone.

16 ucing the thermal antinociceptive effects of oxycodone.

17 at self-administered the prescription opioid oxycodone.

18 days 1 or 15 without the electric barrier or oxycodone.

19 ce aversion in rats chronically treated with oxycodone.

20 and it may enhance the analgesic effects of oxycodone.

21 s used to measure the reinforcing effects of oxycodone.

22 ulate the rewarding and analgesic actions of oxycodone.

23 lgus monkeys were trained to self-administer oxycodone (0.003-0.1 mg/kg/injection) first under a fixe

24 ined male and female rats to self-administer oxycodone (0.1 mg/kg/infusion, 6 h/day) for 14 days.

25 6), and 2- to 3-fold higher adjusted RRs for oxycodone (1.87; 95% CI, 1.66-2.11), morphine (2.84; 95%

26 difference, 1.73; 95% CI, -1.37 to 4.83) and oxycodone (1.89 vs 0.77 doses; difference, 1.13; 95% CI,

27 [CI], 1.06-2.31), acetaminophen 650 mg plus oxycodone 10 mg (MDp, 1.19; 95% CI, 0.85-1.54), ibuprofe

28 Oxycodone 10 mg on days 1 and 5 and the following in a r

29 taminophen (except acetaminophen 650 mg plus oxycodone 10 mg) or placebo.

30 202 pregnancies exposed to codeine, 4540 to oxycodone, 1244 to tramadol, 260 to methadone (dispensed

31 Contrary to oxycodone, 14u produces analgesic activity with reduced

32 lion g), fentanyl (1168%; 3263 to 41,371 g), oxycodone (23%; 1.6 to 2.0 million g), and hydromorphone

33 a (100%), alongside remifentanil (71.4%) and oxycodone (24.3%).

34 decreased for meperidine (39%; 1335 to 806), oxycodone (29%; 4526 to 3190), fentanyl (59%; 59 to 24),

35 Oxycodone 5 mg, codeine 60 mg, and tramadol 37.5 mg plus

36 XN PR or placebo for 16 weeks (starting dose oxycodone 5 mg, naloxone 2.5 mg, twice daily).

37 patient-reported number of tablets taken (in oxycodone 5-mg tablet equivalents).

38 were randomized to either oxycodone rescue (oxycodone, 5 mg, as second-line therapy) or ibuprofen re

39 profen, 600 mg, as second-line therapy, with oxycodone, 5 mg, reserved for breakthrough pain).

40 ablets of placebo; cyclobenzaprine, 5 mg; or oxycodone, 5 mg/acetaminophen, 325 mg.

41 We trained rats to self-administer oxycodone (6 hours/day, 14 days) in context A; infusions

42 he enzymes responsible for the metabolism of oxycodone, a potent prescription opioid.

43 ogen (6OXY(Gly)(4)-KLH) for the treatment of oxycodone abuse.

44 obenzaprine group 19 (IQR,17-21), and in the oxycodone/acetaminophen group 20 (IQR,17-22).

45 n the cyclobenzaprine group, and 11.1 in the oxycodone/acetaminophen group.

46 senting to the ED, adding cyclobenzaprine or oxycodone/acetaminophen to naproxen alone did not improv

47 .3 (98.3% CI, -1.5 to 4.1; P = .28), and for oxycodone/acetaminophen vs cyclobenzaprine, 0.9 (98.3% C

48 as 0.3 (98.3% CI, -2.6 to 3.2; P = .77), for oxycodone/acetaminophen vs placebo, 1.3 (98.3% CI, -1.5

49 acebo and 108 each to cyclobenzaprine and to oxycodone/acetaminophen.

50 potential avenues for interventions against oxycodone addiction.

51 hoice sessions were completed involving oral oxycodone administration (0, 15, and 30 mg/70 kg, p.o.).

52 in dopamine and serotonin after cocaine and oxycodone administration in anesthetized rats in vivo.

53 at an increased overdose risk if they filled oxycodone (aHR, 1.70; 95% CI, 1.04-2.77) or tramadol (aH

54 etine combined with oxycodone, compared with oxycodone alone, significantly decreased the ventilatory

55 he role of RGS9-2 in regulating responses to oxycodone, an MOR agonist prescribed for the treatment o

56 profen and 1000 mg of acetaminophen; 5 mg of oxycodone and 325 mg of acetaminophen; 5 mg of hydrocodo

57 ore from baseline to 2 hours was between the oxycodone and acetaminophen group and the hydrocodone an

58 en group; by 4.4 (95% CI, 3.7 to 5.0) in the oxycodone and acetaminophen group; by 3.5 (95% CI, 2.9 t

59 Here we assessed whether co-consumption of oxycodone and alcohol influence the intake of one anothe

60 plume for nonresonant laser vaporization of oxycodone and atenolol desorbed from steel is 2.4% +/- 1

61 reveal distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organo

62 Subjective effects of oxycodone and drug craving were measured with visual ana

63 trast to methylnaltrexone and hydromorphone, oxycodone and hydrocodone do not interact with OCT1 and

64 enerate immunogens that would recognize both oxycodone and hydrocodone.

65 ion to brain, and blunted analgesia for both oxycodone and hydrocodone.

66 me, to study the electrochemical behavior of oxycodone and its two main metabolites, noroxycodone and

67 Other drugs such as oxycodone and noroxycodone lose water in a single-stage

68 ntly enhanced the antinociceptive effects of oxycodone and reduced naloxone-precipitated conditioned

69 Thus Michael reaction of the benzylimines of oxycodones and oxymorphones with nitrostyrenes gave a se

70 ent required supplemental narcotics (5 mg of oxycodone) and sedatives (1 mg lorezapam), and one patie

71 of the pharmaceutical compounds loratadine, oxycodone, and atenolol deposited on glass, wood, steel,

72 rescribed opioids such as morphine, codeine, oxycodone, and fentanyl are mu-opioid receptor (MOR) ago

73 ioid Supply policy (hydromorphone, morphine, oxycodone, and fentanyl); opioid-related poisoning hospi

74 tance, followed by alcohol, opiate, cocaine, oxycodone, and methamphetamine.

75 paracetamol, codeine, co-dydramol, tramadol, oxycodone, and morphine) during 2005-2010 compared with

76 ed to 3-day substitution tests where saline, oxycodone, and REL-1017 were self-delivered IV by a fixe

77 luence the intake of one another, demand for oxycodone, and the neurocircuitry underlying cue-primed

78 always present in the blood after a dose of oxycodone, and to date, there is no electrochemical data

79 Hydrocodone, codeine, oxycodone, and tramadol were the 4 most commonly prescri

80 Opioids such as morphine and oxycodone are analgesics frequently prescribed for the t

81 Prescription opioids such as oxycodone are highly effective analgesics for clinical p

82 Contrary to oxycodone, as expected from the addition of sigma(1)R an

83 Is oxycodone associated with greater efficacy and fewer adv

84 self-administration and response-contingent oxycodone-associated cues during abstinent reinstatement

85 secutive tests: lever pressing reinforced by oxycodone-associated discrete cues in nondrug context B

86 In this study, oxycodone-based and hydrocodone-based haptens were conju

87 polyclonal B cell population specific for an oxycodone-based hapten (6OXY) was analyzed by flow cytom

88 Fast and accurate determination of oxycodone blood concentration would enable personalized

89 Finally, we demonstrate that oxycodone, but not buprenorphine activated STAT1 and ind

90 a mixture of morphine, codeine, oxymorphone, oxycodone, clozapine, and buspirone and their deuterated

91 althy participants, paroxetine combined with oxycodone, compared with oxycodone alone, significantly

92 y assessed for paroxetine or quetiapine with oxycodone, compared with placebo and oxycodone, on days

93 placebo ibudilast condition under the 15 mg oxycodone condition, but not significantly lower under t

94 but not significantly lower under the 30 mg oxycodone condition.

95 offspring, including impaired extinction of oxycodone-conditioned place preference in males.

96 d neuronal activity increased following oral oxycodone consumption during self-administration and res

97 ntly introduced a rat model of incubation of oxycodone craving after electric barrier-induced volunta

98 of vSub neuronal ensembles in incubation of oxycodone craving after voluntary abstinence, but not ho

99 ng late than early abstinence (incubation of oxycodone craving).

100 r nanoparticle (hNP)-based vaccine targeting oxycodone demonstrated superior immunogenicity and effic

101 lly administered monoclonal antibody reduces oxycodone-derived effects.

102 ys 1 and 5, whereas quetiapine combined with oxycodone did not cause such an effect.

103 gle in vivo exposure to the opioid analgesic oxycodone disrupted mu OP-LTD and endocannabinoid-LTD, b

104 rum Ab titers and their efficacy in blocking oxycodone distribution to the brain and oxycodone-induce

105 g) were studied in combination with the peak oxycodone dose and a dose on the descending limb of the

106 ratio schedule of reinforcement, shifted the oxycodone dose-response curve downward, and inhibited ox

107 X decreased responding on the peak of the FR oxycodone dose-response curve, but increased responding

108 hen only, while 19 (37%) consumed at least 1 oxycodone dose.

109 remained slight during the study, with mean oxycodone doses of 114 mg/d (range, 20 to 400 mg/d) for

110 nd the remaining 13 (26%) consumed 1 or more oxycodone doses.

111 pe reduced oxycodone self-administration and oxycodone-enhanced brain-stimulation reward.

112 oderate to severe pain were randomized to CR oxycodone every 12 hours (n=81) or IR oxycodone four tim

113 CR oxycodone every 12 hours was as effective as IR oxycodon

114 d did not produce adverse feeding effects in oxycodone-experienced rats.

115 We developed a mouse model of oxycodone exposure and subsequent withdrawal in the pres

116 Chronic oxycodone exposure did not affect gut microbiome and int

117 resent study investigated effects of chronic oxycodone exposure on mood-related behaviors (depression

118 dose-response curve downward, and inhibited oxycodone extinction responding and reinstatement of oxy

119 ng, using intravenous self-administration of oxycodone, fentanyl, and buprenorphine in rats allowed l

120 We found that animals that self-administered oxycodone, fentanyl, or heroin, but not buprenorphine ha

121 (SA), Sprague-Dawley rats self-administered oxycodone for 20 days using short-(ShA, 3 h) and long-ac

122 to CR oxycodone every 12 hours (n=81) or IR oxycodone four times daily (n=83) for 5 days in a multic

123 codone every 12 hours was as effective as IR oxycodone four times daily in managing moderate to sever

124 isrupting muOR signaling in the DPn switched oxycodone from rewarding to aversive and exacerbated the

125 An oxycodone hapten containing a tetraglycine linker at the

126 for almost a century, but effects of chronic oxycodone have been studied less than morphine in precli

127 abuse deterrence via the nasal route for an oxycodone HCl ER tablet drug product may include methods

128 and formulation type for nasally insufflated oxycodone HCl immediate release (IR) and ER tablets.

129 Oxycodone hydrochloride (HCl) extended release (ER) tabl

130 Initiation at discharge of oxycodone hydrochloride 5 mg of 10 mg (ie, 1 or 2 tablet

131 This study compared the clinical efficacy of oxycodone hydrochloride controlled-release (CR) tablets

132 o reduce wide-scale abuse of the proprietary oxycodone hydrochloride formulation OxyContin, an abuse-

133 r representative opioids (morphine, codeine, oxycodone, hydrocodone) and five stimulants (amphetamine

134 Using FSA, oxycodone, hydrocodone, fentanyl, and their urinary meta

135 ere we report a small volume urine assay for oxycodone, hydrocodone, fentanyl, noroxycodone, norhydro

136 tions of six prescription opioid analgesics: oxycodone, hydrocodone, hydromorphone, fentanyl, morphin

137 other abused opioids, including hydrocodone, oxycodone, hydromorphone, oxymorphone, and codeine.

138 dmitting to the doctor that he had purchased oxycodone illegally.

139 to severe acute pain and cancer pain, use of oxycodone imposes a risk of adverse effects such as addi

140 Thus, alcohol alters the motivation to seek oxycodone in a sex-dependent manner and the neural circu

141 esic activity, comparable to the MOR agonist oxycodone in animal models of acute and chronic pain aft

142 suring clinically relevant concentrations of oxycodone in buffer solution.

143 ving), reinforcing, and analgesic effects of oxycodone in human volunteers diagnosed with opioid depe

144 ositively regulates the rewarding effects of oxycodone in pain-free states, and in a model of neuropa

145 n this cohort study of US adults, initiating oxycodone in patients treated with paroxetine or fluoxet

146 esic activity, comparable to the MOR agonist oxycodone in the paw pressure test in mice.

147 oth electrode types could selectively detect oxycodone in the presence of noroxycodone and oxymorphon

148 imester 2 (aRR, 3.01; 95% CI, 1.80-5.03) and oxycodone in trimester 3 (aRR, 2.43; 95% CI, 1.37-4.02)

149 .e., cocaine, fentanyl, methamphetamine, and oxycodone) in wastewater were used as the analyte:sample

150 Desirable high cross-reactivity to oxycodone, in addition to other common opiates, morphine

151 Chronic oxycodone induced a depression-like effect, but not anxi

152 However, oxycodone induced type I interferon signaling in many ce

153 letion from GABAergic neurons did not affect oxycodone-induced analgesia, hypothermia, or conditioned

154 Oxycodone-induced antinociception was attenuated by NTX,

155 king oxycodone distribution to the brain and oxycodone-induced behavior in mice.

156 rtly sex-specific manner and prevented acute oxycodone-induced brain hypoxia.

157 ose-dependently inhibited the acquisition of oxycodone-induced conditioned place preference (CPP) in

158 V130 maintenance would protect against acute oxycodone-induced decreases in nucleus accumbens oxygen

159 tudies have investigated the pathogenesis of oxycodone-induced depression.

160 , D(3)R knockout in dopamine neurons reduced oxycodone-induced hyperactivity and analgesia, while del

161 Compound 19 inhibited oxycodone-induced hyperlocomotion in mice and reduced ox

162 -induced hyperlocomotion in mice and reduced oxycodone-induced locomotor sensitization.

163 codynamics, since TLR4(-/-) mice had reduced oxycodone-induced p38 and JNK phosphorylation, while dis

164 ne extinction, each compound was examined on oxycodone-induced reinstatement.

165 +/-)VK4-40, but not (+/-)VK4-116, attenuated oxycodone-induced reinstatement.

166 those using inhibiting SSRIs at the time of oxycodone initiation was higher than in those using othe

167 ]) were receiving other SSRIs at the time of oxycodone initiation.

168 xetine) vs use of other SSRIs at the time of oxycodone initiation.

169 Outcomes were assessed within 365 days of oxycodone initiation; in primary analyses, patients were

170 LgA rats escalated their oxycodone intake and separated into lower (LgA-L) or hig

171 Male and female rats underwent oxycodone intravenous self-administration (IVSA) with ho

172 n Study Rats were trained to self-administer oxycodone intravenously (IV) and then were subjected to

173 Oxycodone is a strong opioid frequently used as an analg

174 Oxycodone is one of the most prescribed opioid medicatio

175 Oxycodone is the most prescribed opioid for pain managem

176 Rats treated with oxycodone maintained stable self-injection, as expected

177 (MMEs) was 65 with buprenorphine and 70 with oxycodone (median difference, -1 mg; 95% CI, -10 to 10 m

178 in was 0.16 with buprenorphine and 0.17 with oxycodone (median difference, 0.01; 95% CI, -0.02 to 0.0

179 CU day was 22 with buprenorphine and 22 with oxycodone (median difference, 1 mg; 95% CI, -2 to 5 mg;

180 istics varied across opioids, with tramadol, oxycodone, methadone, hydromorphone, and morphine being

181 ine > fentanyl = oxymorphine > butorphanol = oxycodone = nalbuphine.

182 Using oxycodone, naloxone, and an IgG-sized antibody as releva

183 the analgesic efficacy of prolonged-release oxycodone-naloxone (OXN PR) in patients with Parkinson's

184 Tapentadol and oxycodone-naloxone are found to exhibit better tolerabil

185 Tapentadol was followed by oxycodone-naloxone combination in providing better toler

186 ent satisfaction was found to be higher with oxycodone-naloxone followed by fentanyl and tapentadol.

187 Innate immune responses to the anti-oxycodone nanovaccines were tested in murine macrophage

188 th paroxetine plus oxycodone vs placebo plus oxycodone on day 1 (29.2 vs 34.1 L/min; mean difference

189 th quetiapine plus oxycodone vs placebo plus oxycodone on day 1 (33.0 vs 34.1 L/min; MD, -1.2 L/min [

190 ne with oxycodone, compared with placebo and oxycodone, on days 1 and 5 (primary) and for paroxetine

191 -2 does not affect the analgesic efficacy of oxycodone or the expression of physical withdrawal, it o

192 lowed up until the discontinuation of either oxycodone or their index SSRI group.

193 ed anesthetics nor with methadone, naloxone, oxycodone, or heroin.

194 each year, in 2010 usually for hydrocodone, oxycodone, or tramadol.

195 ere treated with buprenorphine sublingual or oxycodone oral/enteral during ICU admission.

196 Buprenorphine sublingual is as effective as oxycodone oral/enteral with regard to pain control and o

197 who received buprenorphine sublingual versus oxycodone oral/enteral.

198 Maternal oxycodone (OXY) exposure of pregnant mice leads to distu

199 ehavior and withdrawal induced by the opioid oxycodone (OXY) in male mice but not in females, and thi

200 (VEH), buprenorphine (BUP) to model MOUD, or oxycodone (OXY), to model peripartum drug use, before, d

201 without known immunosuppressive properties (oxycodone, oxymorphone, tramadol) accounting for demogra

202 effects than patients with CKD who received oxycodone (P = .010).

203 re reported with CR (109) than with IR (186) oxycodone (P=.006).

204 orphine, fentanyl, hydromorphone, methadone, oxycodone, papaveretum, pentazocine, pethidine, tapentad

205 surgeries, the median consumption was 3 5 mg oxycodone pills or less.

206 other analgesics, apart from an increase in oxycodone poisonings, but numbers were small.

207 icaid (OR, 1.20; 95% CI, 1.11-1.31), whereas oxycodone positivity was greatest for women (OR for men,

208 Morphine, buprenorphine, and oxycodone prescribing rates continued to rise steadily t

209 IL-17A Ab co-administration with oxycodone prevented the depression-like effect and hyper

210 u-opioids including fentanyl, methadone, and oxycodone produced acute analgesic tolerance that was bl

211 Medications prescribed were codeine, oxycodone, propoxyphene, tramadol, morphine, meperidine,

212 ic doses, 15au showed less constipation than oxycodone, providing evidence that dual MOR agonism and

213 mygdala neurons activated during sucrose and oxycodone reinstatement and the number of ventral and do

214 isplayed activation patterns consistent with oxycodone reinstatement.

215 rrier-induced abstinence predicted incubated oxycodone relapse.

216 Our results identify a role for IL-17A in oxycodone-related behavioral and neuroimmune effects and

217 om there, patients were randomized to either oxycodone rescue (oxycodone, 5 mg, as second-line therap

218 low-up and noncompliance, 51 remained in the oxycodone rescue group and 49 in the ibuprofen rescue gr

219 Thirty-two (63%) in the oxycodone rescue group had adequate pain management with

220 of 118 patients were randomized (62 [52.5%] oxycodone rescue, 56 [47.5%] ibuprofen rescue; mean [SD]

221 2.7-3.2) million who misused hydrocodone and oxycodone, respectively.

222 ssful detection of a commonly abused opiate, oxycodone, resulted in 100% qualitative agreement betwee

223 These findings suggest that escalated oxycodone SA results in MSK1/2-dependent histone phospho

224 ndent of sex, the time-dependent increase in oxycodone seeking after cessation of opioid self-adminis

225 bated (day 15) but not non-incubated (day 1) oxycodone seeking after either voluntary or forced absti

226 determine the causal role of mOFC and DMS in oxycodone seeking after electric barrier-induced abstine

227 lateral to claustrum decreased incubation of oxycodone seeking after electric barrier-induced abstine

228 a role of DMS and related brain circuits in oxycodone seeking after voluntary abstinence, suggesting

229 es, (-)-OSU6162 modestly decreased incubated oxycodone seeking after voluntary but not forced abstine

230 TRV130 decreased oxycodone seeking and taking during abstinence in a part

231 We then tested prevention of oxycodone seeking and taking during abstinence using a m

232 on of DMS (p < 0.001) but not mOFC decreased oxycodone seeking before or after electric barrier-induc

233 esponding), context-induced reinstatement of oxycodone seeking in context A, and reacquisition of oxy

234 effect of (-)-OSU6162 (7.5 and 15 mg/kg) on oxycodone seeking on abstinence day 1 or after 15 days o

235 gonists) and then tested them for relapse to oxycodone seeking on abstinence days 1 or 15 without the

236 Oxycodone seeking was greater during late than early abs

237 ce days 1, 15, or 30, we tested the rats for oxycodone seeking without shock and drug.

238 strum-related circuits predict incubation of oxycodone seeking.

239 hat was negatively correlated with incubated oxycodone seeking.

240 hat was positively correlated with incubated oxycodone seeking.

241 VTA glutamate neurons reduced abstinent oral oxycodone-seeking behavior in male but not female mice.

242 self-administration and the reinstatement of oxycodone-seeking behavior in rats.

243 self-administration and the reinstatement of oxycodone-seeking behavior without affecting ad libitum

244 e extinction responding and reinstatement of oxycodone-seeking behavior.

245 uitry underlying cue-primed reinstatement of oxycodone-seeking.

246 d by cue-primed reinstatement of sucrose and oxycodone-seeking.

247 To identify signaling pathways activated by oxycodone self-administration (SA), Sprague-Dawley rats

248 etion of D(3)R from either cell type reduced oxycodone self-administration and oxycodone-enhanced bra

249 directly into the accumbens shell attenuated oxycodone self-administration and the reinstatement of o

250 the GLP-1 receptor agonist exendin-4 reduced oxycodone self-administration and the reinstatement of o

251 d extinction responding and reacquisition of oxycodone self-administration but had a weaker (nonsigni

252 Here, we show in rats that maternal oxycodone self-administration during pregnancy leads to

253 Oxycodone self-administration experience increased OFC f

254 e seeking in context A, and reacquisition of oxycodone self-administration in context A.

255 (1 mug per site) reversed the escalation of oxycodone self-administration in HA rats but not in LA r

256 Moreover, 27b also inhibited oxycodone self-administration in male Sprague-Dawley rat

257 K4-116 also lowered the break-point (BP) for oxycodone self-administration under a progressive-ratio

258 inhibited the acquisition and maintenance of oxycodone self-administration.

259 t (+/-)VK4-116, significantly decreased peak oxycodone self-administration; (+/-)VK4-40 did not incre

260 ted the analgesic actions of hydrocodone and oxycodone, shifting their ED(50) values by 2.5-fold and

261 munization, correlated to subsequent greater oxycodone-specific serum Ab titers and their efficacy in

262 MS imaging of the spatial distribution of an oxycodone spot on a metal slide with resolution of 250 m

263 din-4 did not alter the analgesic effects of oxycodone, suggesting that activation of GLP-1 receptors

264 d every 12 hours with immediate-release (IR) oxycodone tablets administered four times daily in patie

265 nally resorted to purchasing one or two 5-mg oxycodone tablets in the open-air drug market operating

266 . ibuprofen and a prescription for five 5-mg oxycodone tablets, enrolled him in the clinic's diabetes

267 parated into lower (LgA-L) or higher (LgA-H) oxycodone takers.

268 ncluding morphine, methadone, hydromorphone, oxycodone, tapentadol, fentanyl, sufentanil, and remifen

269 1% lower odds of receiving a prescription of oxycodone than white patients (P < .001).

270 n with opioid agonists, such as morphine and oxycodone, that develop more rapidly than the tolerance

271 antitative analysis of the drugs cocaine and oxycodone, the agrochemicals atrazine and azoxystrobin,

272 gainst the highly abused prescription opioid oxycodone, the polyclonal B cell population specific for

273 f opioid use by pregnant women who first use oxycodone then switch to methadone maintenance pharmacot

274 ctivates hydrocodone, tramadol, codeine, and oxycodone to active metabolites that primarily provide a

275 al withdrawal, it opposes the development of oxycodone tolerance, in both acute pain and chronic neur

276 In slices from oxycodone treated animals, no tolerance to opioids was o

277 Furthermore, we found that application of oxycodone, U-50488, or deltorphin II on gastric nodose g

278 ward studying it for use in the treatment of oxycodone use disorder.

279 ped depression has been coupled with chronic oxycodone use in a few clinical studies, but no preclini

280 Gut microbiome changes following oxycodone use is an understudied area, and interleukin-1

281 Among individual opioids, oxycodone users had a lower rate of infection than morph

282 Oxycodone (using an incremental dosing regimen) or salin

283 extended our investigation of the hNP-based oxycodone vaccine to rats and applied the hNP platform t

284 Results demonstrate that hNP-formulated oxycodone vaccines exhibit improved efficacy in rats and

285 significantly decreased with paroxetine plus oxycodone vs placebo plus oxycodone on day 1 (29.2 vs 34

286 significantly decreased with quetiapine plus oxycodone vs placebo plus oxycodone on day 1 (33.0 vs 34

287 Next, economic demand for intravenous oxycodone was assessed while access to alcohol and/or wa

288 nt of rheumatic disease pain with codeine or oxycodone was effective in reducing pain severity and wa

289 without evidence for internalization; and 3) oxycodone was ineffective in both processes.

290 Oxycodone was not associated with superior cancer pain r

291 Oxycodone was the first prescribed opioid in 65% of pati

292 ur generations of the total syntheses of ent-oxycodone were accomplished in 13, 18, 16, and 11 operat

293 n, ratings of drug liking following 15 mg of oxycodone were decreased significantly.

294 Four distinct approaches to ent-oxycodone were designed and accomplished.

295 s cohort study included adults who initiated oxycodone while receiving SSRI therapy between 2000 and

296 A total of 2 037 490 initiated oxycodone while taking SSRIs (1 475 114 [72.4%] women; m

297 The limit of detection for oxycodone with the Nafion/SWCNT sensor was 85 nM, and th

298 Oxycodone withdrawal alone triggered robust gene express

299 s genes and pathways selectively affected by oxycodone withdrawal in mice with peripheral nerve injur

300 HI), attenuated behavioral manifestations of oxycodone withdrawal, especially in mice with neuropathi

301 remifentanil) and the semisynthetic opioid (oxycodone) would also potentiate sustained ASIC currents